Jacobs Levy Equity Management
CDTX

Jacobs Levy Equity Management’s Cidara Therapeutics CDTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29,735
Closed -$1.33M – 983
2021
Q3 		$1.33M Buy
29,735
+7,682
+35% +$292K 0.01% 691
2021
Q2 		$891K Sell
22,053
-11,710
-35% -$495K 0.01% 760
2021
Q1 		$1.8M Buy
33,763
+18,982
+128% +$937K 0.01% 620
2020
Q4 		$591K Buy
+14,781
New +$735K 0.01% 827
2020
Q2 		– Sell
-4,377
Closed -$217K – 1044
2020
Q1 		$217K Sell
4,377
-2,853
-39% -$171K ﹤0.01% 869
2019
Q4 		$555K Buy
+7,230
New +$331K 0.01% 772
2019
Q2 		– Sell
-4,799
Closed -$254K – 952
2019
Q1 		$254K Sell
4,799
-1,285
-21% -$70.5K ﹤0.01% 861
2018
Q4 		$286K Buy
6,084
+145
+2% +$10.3K 0.01% 816
2018
Q3 		$523K Buy
5,939
+1,705
+40% +$150K 0.01% 767
2018
Q2 		$440K Sell
4,234
-969
-19% -$91.5K 0.01% 824
2018
Q1 		$416K Buy
5,203
+1,507
+41% +$206K 0.01% 806
2017
Q4 		$503K Buy
3,696
+1,193
+48% +$181K 0.01% 752
2017
Q3 		$405K Sell
2,503
-705
-22% -$100K 0.01% 736
2017
Q2 		$481K Buy
+3,208
New +$443K 0.01% 706

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jacobs Levy Equity Management's CDTX Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Cidara Therapeutics (CDTX) in Q4 2021, closing a stake of 29,735 shares — an estimated $1.33M sold.

Jacobs Levy Equity Management first reported a position in CDTX in Q2 2017 and held it in 14 quarters. The position peaked at $1.8M in Q1 2021. 52 funds tracked by Wall St. Rank hold CDTX as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Cidara Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 29,735 Cidara Therapeutics shares in Q4 2021, an estimated $1.33M.
  • Jacobs Levy Equity Management first reported a position in Cidara Therapeutics in Q2 2017 and held it in 14 quarters.
  • Jacobs Levy Equity Management's Cidara Therapeutics position peaked at $1.8M in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.